Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corvus Pharma Com (NQ: CRVS )

9.100 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corvus Pharma Com

< Previous 1 2 3 4 5 Next >
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Corvus Pharma
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. 
Via Benzinga
Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2
Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics. 
Via Talk Markets
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
3 High-Potential Penny Stocks to Buy Now
When it comes to penny stocks to buy now, be aware of the risks. While some of these little guys can rocket, some will be duds. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
Corvus Pharmaceuticals Earnings Preview
Via Benzinga
Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence
Via Benzinga
Why Are Corvus Pharmaceuticals Trading Higher Today
In its Q1 earnings release, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) revealed updated data from the Phase 1/1b trial evaluating single-agent therapy with CPI-818 in patients with  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
The 3 Best Biotech Stocks Under $1 to Buy for April
While risky, here are some of the best biotech stocks under $1, with solid catalysts, investors may want to consider. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad... 
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And More
The Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.